Q2 2018: Incorporation of Cleara Biotech B.V. through a joint effort by Apollo Health Ventures and dr. Peter de Keizer
Q4 2019: Cleara becomes the main industrial partner of the ZonMw/Health~Holland Public Private Initiative Voila/SMARTage
Q4 2020: Addition of “Cambrian Bioventures” to investment syndicate
2021-22: Establishment of CL04177 and CL04183 as lead candidates
2022: Sizeable investment by Apollo VC-led syndicate, involving Curie Capital, ROM Utrecht, LongevityTech.Fund and ISTAR Biotech B.V.
Q2 2022: Cleara further expands three teams on preclinical development (I), R&D arm to complete preclinical development and further expand its research pipeline